Veozah Side Effects Linked to Severe Liver Injury Risks: FDA

Veozah Side Effects Linked to Severe Liver Injury Risks FDA

Federal drug regulators warn that side effects of Veozah, a prescription treatment for hot flashes during menopause, may increase the risk of severe liver injuries to women.

The U.S. Food and Drug Administration (FDA) issued a Veozah drug safety communication on September 12, urging users to stop taking the drug if they experience signs and symptoms of liver injury. The agency also ordered new warnings about the potential risk of liver injury to be added to the drug’s label, indicating that doctors should conduct hepatic laboratory testing before and during use.

Veozah (fezonlinetant) is a medication manufactured by Astellas Pharma, which was approved by the FDA for the treatment of moderate to severe hot flashes during menopause in 2023. It belongs to a class of medications known as neurokinin 3 (NK3) receptor agonists, which affect the brain’s control of body temperature.

The new FDA warning comes after the agency received a report of a woman suffering a serious drug-induced liver injury believed to be caused by Veozah side effects, which surfaced during the second month after treatment began.

To avoid the risk of problems among other patients, the agency is recommending that healthcare providers increase the frequency of liver function testing, adding monthly evaluations during the first two months after starting Veozah, and then repeating the testing at months three, six and nine, which was already recommended in the drug label.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

“The FDA added a warning about the risk of liver injury to the existing warning about elevated liver function test values and required liver function testing in the prescribing information for Veozah,” federal regulators said. “The FDA made this update after reviewing a post marketing report of a patient with elevated liver function test values and signs and symptoms of liver injury after taking the medicine for about 40 days.”

Regulators are now advising doctors to advise their patients to stop using the drug immediately upon any signs or symptoms of liver injury from Veozah. Symptoms of Veozah liver injury can include:

  • Fatigue
  • Nausea
  • Vomiting
  • Unusual itching
  • Light-colored stools
  • Yellow eyes or skin (jaundice)
  • Dark urine
  • Stomach swelling
  • Right upper abdomen pain

Health care professionals are also urged to warn patients not only about the risk of elevated liver functions when taking Veozah, but also that they may face a risk of rare, but potentially serious liver injuries as well. They should discuss the signs and symptoms of liver injury with patients and warn them to immediately stop using the drug if any of the above symptoms are present.

The FDA urges consumers and doctors to report Veozah liver injuries to the FDA Medwatch adverse event reporting program.


0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

After a growing body of evidence has linked use of the Depo-Provera birth control shot to an increased risk of brain tumors, thousands of women nationwide are seeking information on how to sign up for the Depo-Provera lawsuit.
As lawyers continue to review records on more than 500 Suboxone tooth decay lawsuits, the MDL judge has outlined the process for identifying a smaller group that will move into the next discovery phase.
A federal judge wants lawyers involved in hair relaxer lawsuits to provide an update this week on the status of discovery proceedings for a pool of cases being considered for bellwether trial dates.